DrugPatentWatch Database Preview➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing
« Back to Dashboard
Tandutinib is an investigational drug.
There have been 6 clinical trials for Tandutinib. The most recent clinical trial was a Phase 2 trial, which was initiated on October 1st 2006.
The most common disease conditions in clinical trials are Glioblastoma, Gliosarcoma, and Leukemia, Myeloid, Acute. The leading clinical trial sponsors are National Cancer Institute (NCI), Millennium Pharmaceuticals, Inc., and [disabled in preview].
Recent Clinical Trials for Tandutinib
|Safety Study of the Combination of Tandutinib With Temozolomide and Bevacizumab After Radiation and Temozolomide in Patients With Newly Diagnosed With Glioblastoma Multiforme||Millennium Pharmaceuticals, Inc.||Phase 1|
|Tandutinib Plus Bevacizumab to Treat Recurrent Brain Tumors||National Cancer Institute (NCI)||Phase 2|
|Tandutinib in Treating Patients With Recurrent or Progressive Glioblastoma||National Cancer Institute (NCI)||Phase 1/Phase 2|